https://www.selleckchem.com/products/pp2.html Small bowel capsule endoscopy (SBCE) is the gold standard in the study of small bowel bleeding (SBB). Recent studies suggested that longer small bowel transit times (SBTT) may be associated with higher diagnostic yield of SBCE. The aim of the study is to investigate if longer SBTT is a predictive factor of positive findings on SBCE in a population that performed SBCE due to suspected SBB. Retrospective single-center study, including consecutive SBCE between May 2012 and May 2019 due to suspected SBB. Positive SBCE was considered in the presence of lesions with high bleeding potential, such as ulcers, angioectasias and tumors (P2 lesions, according to the Saurin classification). We included 372 patients, 65.9% female, with median age 67 (IQR 19-97) years. We observed that patients with P2 lesions (n=131; 35.2%) in SBCE presented longer SBTT (p=0.01), were older (p<0.001), more frequently male (p=0.019), suffered more frequently from arterial hypertension (p=0.011), diabetes (p=0.042), chronic kidneyant lesions.Background The efficacy and safety after switching to biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD) has been studied, but, few cohort studies compare the pharmacokinetic profiles, immunogenicity and safety of the reference infliximab (IFX) and CPT-13 in real clinical setting. Objective To compare the pharmacokinetic profiles and drug survival on the long-term outcome of reference IFX and CPT-13 at weeks 54 and 104. A secondary objective was to determine the immunogenicity and safety profile on long-term patients with IBD in a real clinical setting. Methods A retrospective observational cohort analysis in a single centre was performed of patients with IBD in treatment with reference IFX or CPT-13. Serum drug concentrations were compared to determine if there were significant differences in pharmacokinetic outcomes between the reference IFX and CPT-13 at 26, 54, 78 and 104 week. The